Q-1178 , 45th Parliament, 1st session May 26, 2025, to present

With regard to federal funding and programs related to diabetes prevention, management, and treatment, as well as other preventive health measures, since January 2016: (a) what are the total federal expenditures on diabetes-related programs, broken down by fiscal year and by department or agency; (b) what are the details of all grants and contributions made to organizations for diabetes-related research, prevention, education, or treatment, including, for each, the (i) recipient organization, (ii) date, (iii) amount, (iv) program under which the funding was provided, (v) project description, (vi) measurable outcomes or deliverables required under the funding agreement, (vii) reporting received from the recipient on outcomes; (c) what is the total federal expenditure incurred in relation to the Framework for Diabetes in Canada, broken down by fiscal year and by initiative; (d) what specific outcomes have been achieved under the Framework for Diabetes in Canada to date, including, but not limited to, changes in (i) diabetes incidence rates, (ii) diabetes prevalence rates, (iii) diabetes-related hospitalizations, (iv) diabetes-related amputations, (v) diabetes-related mortality; (e) what performance indicators are used to measure the success of the framework, and what are the results for each indicator since the framework's adoption; (f) what evaluations or audits of the framework have been conducted, and what were the findings and recommendations of each; (g) what specific actions has the government taken in response to the findings and recommendations referenced in (f); (h) what is the federal government's working definition of "preventative health"; (i) what is the total federal expenditure on preventative health initiatives, broken down by (i) year, (ii) department or agency; (j) what is the total federal expenditure on disease treatment and management initiatives, broken down by (i) year, (ii) department or agency; (k) what is the ratio of preventative health spending to treatment-focused spending; (l) what comparative analyses has the government conducted of Canada's preventative health spending versus that of other Organisation for Economic Co-operation and Development countries, and what were the conclusions; (m) has the government adopted any specific target or benchmark for the proportion of health spending that should be directed to prevention, and, if so, what is (i) that target, (ii) the current progress against it; and (n) what return-on-investment analyses have been conducted on specific preventative health programs, and what were the findings?